The use of angiotensin-converting enzyme (ACE) inhibitors to treat hypertension has recently increased. However, their use is associated with a persistent dry cough in a significant percentage of such patients. The present study was designed to assess the contribution of polymorphisms as a genetic marker of ACE-inhibitorrelated cough in a Japanese hypertensive population. Genotyping was carried out in 190 patients, 70 with cough and 120 without cough, who had been treated with ACE inhibitors. Polymorphisms of ACE insertion/ deletion (I/D), angiotensin II type 1 receptor (1166A/C), type 2 receptor (3123C/A), and bradykinin B2 receptor (À58T/C, exon 1, I/D), were analyzed in these subjects. The TT genotype and T allele of bradykinin B2 receptor (À58T/C) were identified at a significantly higher frequency in the cough (+) patients than in the cough (À) patients. This difference was even more pronounced in women. However, there was no significant relationship between polymorphisms of ACE, angiotensin II receptors, or bradykinin B2 receptor exon 1, and occurrence of ACE-inhibitor-related cough. The transcriptional activity of the bradykinin B2 receptor promoter is involved in the occurrence of cough, and this new marker may provide a valuable tool to detect patients at risk of developing this side effect of ACE inhibitors. In conclusion, Susceptibility to develop cough is associated with a genetic variant of the bradykinin B2 receptor promoter; thus, it may be possible to identify those patients who will develop this adverse reaction to ACE inhibitors in advance.
Introduction
In the past few decades, we have seen a remarkable development in the treatment of hypertension, and recently the clinical use of angiotensin-converting enzyme (ACE) inhibitors to treat hypertension has significantly increased. Several studies suggest that ACE inhibitors contribute to left ventricular remodelling after hypertensive heart disease, congestive heart failure, and acute myocardial infarction. [1] [2] [3] [4] [5] [6] [7] The suppression of angiotensin II is the main antihypertensive mechanism of action of ACE inhibitors, while the increase of kinin levels has been proposed to contribute to the other beneficial effects of ACE inhibitors, including antihypertensive and cardioprotective effects. However, ACE inhibitors also have adverse effects, and a persistent dry cough is well known as the most common side effect of ACE inhibitors. ACE-inhibitor-related cough occurs in about 10% of treated patients, [8] [9] [10] and in some instances, an unexplained persistent cough limits the use of these drugs. It is unclear why cough occurs in only certain individuals. ACE is identical to kininase II, which is partly responsible for the degradation of kinins; therefore, cough following ACE inhibitors may be a kinin-related phenomenon since ACE inactivates tussive peptides such as bradykinin in the airways. Local accumulation of bradykinin has been suggested to play a major role in ACE-inhibitor-related cough, but the precise mechanism is still unknown. On the other hand, several authors have speculated on the possibility of a genetic predisposition to develop these adverse reactions and they have specifically implicated variants of the genes encoding ACE, chymase and bradykinin B2 receptor. 11, 12 Especially, the insertion (I)/deletion (D) polymorphism of ACE has been used as a genetic marker to investigate the relationship between ACE genotype and cough sensitivity. I/D polymorphism of the ACE is associated with serum ACE activity, and patients with the II genotype have the lowest serum ACE levels compared with the ID and DD genotypes; therefore the II genotype would be associated with an increased risk of developing cough. 11 Furthermore, we have previously shown that susceptibility to cough induced by ACE inhibitors is associated with bradykinin B2 receptor À58 thymine (T)/cytosine (C) polymorphism and that patients with the T/T genotype are more susceptible to cough than patients with other genotypes in the Japanese population. 13 Moreover, Braun et al 14 reported that the luciferase promoter assay of À58T in the bradykinin B2 receptor showed that the expression of the promoter was higher than that of À58C, which further supports our findings. Accordingly, we concluded that the transcriptional activity of the receptor promoter might be involved in the appearance of ACE-inhibitor-related cough. In order to confirm and extend our previous observation, in the present study, we examined a large number of patients including those evaluated in our previous report concerning the bradykinin B2 receptor genes promoter polymorphism, and also examined another candidate gene for ACE-inhibitor-related cough such as ACE, angiotensin II type 1 receptor, angiotensin II type 2 receptor, and bradykinin B2 receptor (exon 1) genes. We investigated the distribution of five polymorphisms in Japanese patients with a history of ACE-inhibitor-related cough to see whether there was a genetic variant that could affect the expression and function of the receptors and clinical symptoms.
Methods

Study population
We studied the genetic susceptibility of hypertensive patients to develop ACE-inhibitor-related cough by examining the polymorphisms of the ACE, angiotensin II type 1 receptor, angiotensin II type 2 receptor, and bradykinin B2 receptor genes. We recruited 190 patients who had been given ACE inhibitors for the treatment of essential hypertension. The participants were randomly selected Japanese outpatients treated at our University Hospital and affiliated hospitals in Tokyo, Japan. They were all essential hypertensive subjects for more than 2 years since they were diagnosed as having essential hypertension, and being free of complications such as coronary heart disease, hyperlipidaemia, diabetes mellitus, etc, requiring treatment. Subjects with any secondary cause of hypertension were also excluded. None of them had a history of recent respiratory infection, other respiratory diseases, or pulmonary congestion. We classified the study population into a cough (+) group and a cough (À) group. For patients in the cough (+) group (n ¼ 70, aged 51 years), previous therapy with ACE inhibitors had to be withdrawn because of the development of cough within 2 weeks after starting therapy. They had been treated with Enalapril, Lisinopril or Imidapril at a daily dose. These patients had complained of dry cough, and all their symptoms had disappeared soon after withdrawal of the ACE inhibitors. Around 200 patients in the cough (À) group were randomly selected Japanese essential hypertensive outpatients treated at the hospital, and patients around 52 years (47 years-55 years) in the cough (À) were randomly selected again to match for age and sex to those in the cough (+) group (n ¼ 120, aged 52 years). They had no complaints of cough and continued treatment of essential hypertension with ACE inhibitors for more than 1 year. Blood samples were collected from the peripheral vein, and the subjects' DNA was extracted from leukocytes using the QIAamp kit (QiaGen, Japan) according to the standard protocol. Written informed consent to participate in the study was obtained from each patient, and the study protocol was approved by our University Hospital Ethics Committee.
Determination of genotypes
(1) ACE I/D polymorphism: The I/D polymorphism of the ACE gene was identified by polymerase chain reaction (PCR) using a set of oligonucleotide primers flanking the polymorphic site according to the method described by Rigat et al. 15 A set of primers was designed to encompass the polymorphic region in intron 16 of the ACE gene (sense primer 5 0 -CTGGAGACCACTCCCATCCTTTCT-3 0 and anti-sense primer 5 0 -GATGTGGCCATCA-CATTCGTCAGAT-3 0 ). The PCR reaction mixture contained 100 ng of the DNA template, 5 pmol/ml of each primer, 1 ml of 2 mmol/L DNTP, 1 ml of 5% DMSO, 0.04 ml of ampli Taq DNA polymerase, and 2 ml of PCR buffer. Amplification was carried out using a thermal cycler (Perkin Elmer 2400). DNA was amplified for 30 cycles; each cycle consisted of denaturation at 941C for 1 min, annealing at 581C for 1 min, and extension at 721C for 1 min, with a final extension time of 7 min. The PCR products were separated by electrophoresis on a 2% agarose gel.
(2) Angiotensin II type 1 receptor 1166 adenine(A)/ cytosine(C) polymorphism: The angiotensin II type 1 receptor 1166A/C polymorphism was identified by PCR and restriction isotyping using the restriction endonuclease Dde 1 and the primers previously described by Doria et al. 16 The primers were as follows: sense, 5 0 -ATAATGTAAGCTCATCCACC-3 0 ; antisense, 5 0 -GAGATTGCATTTCTGTCAGT-3 0 . The 30 ml reaction mixture contained 100 ng genomic DNA, 10 pmol of each primer, 250 m mol/L dNTP, 1.0 mmol/L MgCl 2 , 50 mmol/L KCl, 10 mmol/L Tris-HCI at pH 8.3, and 0.5 units of Taq polymerase. Cycle conditions for PCR were heating for 5 min at 941C, followed by 40 cycles of 30 sec at 941C, 45 s at 551C, and 45 s at 721C as the main reaction, followed by final extension at 721C for 10 min. Then, PCR products were digested with Dde 1 for 3 h at 371C. The digested products were electrophoresed on a 2% agarose gel and visualised by ethidium bromide staining.
(3) Angiotensin II type 2 receptor cytosine(C)/ adenine(A) polymorphism: We used the following primers: sense, 5 0 -GGATTCAGATTTCTCTTTGAA-3 0 ; antisense, 5 0 -GCATAGGAGTATGATTTAATC-3 0 . PCR was performed under the same conditions used to amplify the angiotensin II type 1 receptor gene, except that the annealing temperature was set at 531C. After confirming DNA amplification, 10 ml of the PCR product was digested with 12 units of Alu 1 for 3 h at 371C, then el ectrophoresed on a 2% agarose gel and visualised by ethidium bromide staining. 17, 18 (4) Bradykinin B2 receptor À58 thymine(T)/cytosine(C) polymorphism: The primers were as follows: sense, 5
0 -GCAGAGCTCAGCTGGAGGAG-3 0 , located in the promoter, antisense, 5
0 -CCTCCTCGGAGCC-CAGAAG-3 0 , located in the promoter/exon 1. The primers were designed from the bradykinin B2 receptor gene reported by Kammerer et al. 19 The total reaction volume was 100 ml, and contained 1 mg of genomic DNA, 50 ng of each primer, 200 mmol of each dNTP, 1.5 mmol/L of MgCl 2 , and 0.5 units of Taq DNA polymerase. The conditions for PCR were an initial step of 5 min at 941C, followed by 30 cycles of 1 min at 941C, 30 s at 581C, and 30 s at 721C, and final extension for 5 min at 721C. The PCR products were subjected to single-strand conformation polymorphism (SSCP) electrophoresis. A 10 ml aliquot of the PCR product was diluted with 30 ml formamide, denatured at 951C for 10 min, and subjected to SSCP analysis in a 20% polyacrylamide (2 Â TBE) gel. Electrophoresis was carried out in 2 Â TBE buffer at 241C and 180 V for 20 h, and the gels were then silver-stained. Several samples representative of each genotype detected by SSCP were sequenced by fluorescent cycle sequencing to confirm the presence of T or C at nucleotide position À58 upstream of the putative transcription start site.
(5) Bradykinin B2 receptor exon 1 I/D polymorphism: A tandem repeat polymorphism was detected in exon 1 starting at nucleotide position 12 backward from the transcription site. 19 Thus, exon 1 exists in two different lengths, 102 and 93 bp, that is, I or D, respectively. The primers were designed from the bradykinin B2 receptor gene reported by Kammerer et al. 19 The forward and reverse primers 5 0 -GCCCTTGAAAGATGAGCTG-3 0 and 5 0 -AACTCCC-CACGACCACAG-3 0 were used for PCR amplifications of exon 1. The total reaction volume was 50 ml and included 1 ml genomic DNA, 50 ng of each primer, 1.25 U Taq DNA polymerase, 200 mmol of each dNTP, and 1.5 mM MgCl 2 . The conditions for PCR were an initial step of 5 min at 941C, followed by 1 min at 941C, 1 min at 531C, and 1 min at 721C for 40 cycles and final extension for 5 min at 721C. The PCR products were then electrophoresed on a 2% agarose gel and visualised by ethidium bromide staining.
Statistical analysis
Differences in clinical characteristics between the two groups were examined by ANOVA for parametric data. Genotype and allelic frequencies in the two groups were compared by w 2 analysis. All observed genotype frequencies were in HardyWeinberg equilibrium. A probability of less than Po0.05 was considered as statistically significant.
Results
The clinical characteristics of the study population are shown in Table 1 . Haematological data and blood pressure in both groups were not significantly different. Table 2 shows the distributions of the genotypes and the allelic frequencies of the polymorphisms of ACE, angiotensin II type 1 receptor, angiotensin II type 2 receptor, and bradykinin B2 receptor in cough ( 7 ) patients. In the ACE, no significant difference in the genotypes and the allelic frequencies was observed between the two groups therefore, cough was not significantly related to the ACE genotype. As for the angiotensin II type 1 receptor, there were no significant differences regarding genotypes and the allelic frequencies between the two groups either. Table 2 also shows the allelic frequency of the angiotensin II type 2 receptor polymorphism. The angiotensin II type 2 receptor has been mapped to the X chromosome; thus, here we show only the allelic frequency. The allelic frequency of the angiotensin II type 2 receptor did not differ significantly between the two groups. These results suggest that there is no significant relationship between the angiotensin II receptor polymorphisms and ACE-inhibitor-induced cough. The distributions of the genotypes and allelic frequencies of the bradykinin B2 receptor À58T/C polymorphism in cough ( 7 ) patients are also shown in Table 2 . The distribution of the T/C genotype was as follows: TT 39%, TC 57%, and CC 4% in the cough (+) patients, and TT 11%, TC 57%, and CC 32% in the cough (À) patients. A significantly higher incidence of the TT genotype was seen in the cough (+) patients Age are expressed as mean 7 standard deviations and comparison was performed by ANOVA.
Polymorphisms of ACE-inhibitor-related cough S Mukae et al (Po0.001). In the cough (+) patients, the allelic frequency was 0.67 for the T allele and 0.33 for the C allele, and the frequency of the T allele was significantly higher in these patients than in the cough (À) patients (odds ratio 3.17 (95% confidence interval 2.05-4.92), Po0.001). In addition, Table 2 shows in the distributions of the genotype and the allelic frequencies of the bradykinin B2 receptor gene exon 1 I/D polymorphism; there were no II or ID polymorphisms among these subjects. Furthermore, the distributions of the genotypes and the allelic frequencies of ACE, angiotensin II type 1 receptor, and angiotensin II type 2 receptor polymorphisms by gender showed no significant differences between men and women (data not shown). Table 3 shows the distributions of the genotypes and the allelic frequencies of the bradykinin B2 receptor À58T/C polymorphism by gender. In the subgroup of men with cough, the distribution of the T/C genotype was TT 30%, TC 63%, and CC 7%, which was significantly different from the distribution in the subgroup of men without cough (P ¼ 0.030). In the subgroup of women with cough, the distribution of the T/C genotype was TT 45%, TC 53%, and CC 2%, which was significantly different from the distribution in the subgroup of women without cough (Po0.001). These tendencies were more apparent in the females. Just as in the case of the distribution of the T/C genotype, a significant increase of the T allele was seen in the subgroup of men with cough (the odds ratio was estimated as 2.12 (95% confidence interval 1.11-4.07), P ¼ 0.023). A significant increase of the T allele was also seen in the subgroup of women with 
Discussion
A persistent dry cough is a clinically important adverse reaction to ACE inhibitors, and may occur at any time from a few days to several months after the initiation of treatment. The cough may improve with a reduction in the dose, but it is usually not wholly dose dependent. 20 The symptom seems to be more prevalent in women than in men. 21 It may be related to their effects on the kininogen-kinin system since the breakdown of bradykinin is known to be prevented by ACE inhibitors. Bradykinins act mainly as local hormones by activating specific receptors, known as B1 and B2 receptors, with most of the inflammatory and cardiovascular effects being mediated by the B2 receptor.
22, 23 The human B2 receptor gene has been cloned [24] [25] [26] [27] and mapped to human chromosome region 14q32. 28 The gene is larger than 25 kb and consists of three exons, and cell-surface, G-protein-coupled receptors of the seven-transmembrane-domained superfamily. 29 We have already reported that the C allele at position À58 in the promoter region of the bradykinin B2 receptor was found more frequently among patients with hypertension compared with healthy control subjects in a Japanese population, 30 and another study also obtained similar findings in an AfricanAmerican population. 31 In vitro transfection experiments done by Braun et al 14 support our results; therefore, we suspect that the low transcriptional activity of the bradykinin B2 receptor promoter may influence the transcription rate of the gene, and occurrence of essential hypertension. This bradykinin B2 receptor À58T/C promoter polymorphism may serve as a marker of predisposition to develop essential hypertension.
On the other hand, ACE-inhibitor-related cough is also thought to result from the interaction of multiple genetic factors. The II genotype of the ACE gene would be associated with an increased risk of developing cough, 11 but other studies did not detect such association; 32 thus, there is no established theory about the role of the ACE I/D in the occurrence of ACE-inhibitor-related cough. Differences in population selection or interactions with other genetic polymorphisms may account for these discrepancies. As for the polymorphisms of ACE and angiotensin II receptors, Tiret et al 33 have shown that the relationship between ACE DD genotype and myocardial infarction was closer in a subset of patients who also carried the angiotensin II type 1 C allele. The ACE I/D polymorphism and the angiotensin II type 1 receptor 1166 A/C and type 2 receptor 3123C/A polymorphisms are suspected to be markers in linkage disequilibrium with an unidentified functional variant that could affect the regulation of the gene in response to angiotensin II. 34 Moreover, the cellular effects of angiotensin II are mediated by two structurally distinct receptor subtypes, angiotensin II type 1 and type 2 receptors, and angiotensin II type 1 and type 2 receptors have opposite functions. [35] [36] [37] It is also suspected that angiotensin II receptor stimulates the kininogenkinin system and induces cough; therefore it was interesting for us to examine the association between angiotensin II receptor polymorphisms and ACE-inhibitor-related cough. Our data indicate that there was no association between ACE, angiotensin II type 1 and type 2 receptor genotypes, and the occurrence of ACE-inhibitor-related cough; therefore, the common genetic variants of ACE, angiotensin II type 1 and type 2 receptors do not explain the occurrence of ACE-inhibitor-relatedcough. Another paper reported 11 the relationship between ACE I/D polymorphism and ACE-inhibitorrelated cough, which was mainly associated with female patients, but there are also some controversial reports. 32 This discrepancy may be the result of a population specificity. Thus, from our results and these reports, 11, 32 we concluded that the association between ACE genotype and ACE-inhibitor-related cough was not strong.
On the contrary, based on the polymorphism of bradykinin B2 receptor, we previously reported significant associations between the TT genotype and T allele and ACE-inhibitor-related cough. Patients with the TT genotype were the most prone to develop cough, and those with the CC genotype were the least prone to it, especially among females. 13 In the present study, we examined a large number of patients including those evaluated in our previous report, and observed the same association between bradykinin B2 receptor polymorphism and the predisposition to develop ACE-inhibitor-induced cough. However, the genotype of the bradykinin B2 receptor exon 1 did not influence ACEinhibitor-related cough. Braun et al 14 initiated in vitro transfection experiments using human embryonic kidney cells and performed luciferase reporter gene assays to examine how the transcription rate was affected by the different alleles of the promoter. The two different alleles of the promoter region showed differences in the extent of luciferase expression, that is to say, the luciferase reporter gene assay of À58T was found to be higher than that of À58C. Kammerer et al 19 reported that the promoter of the bradykinin B2 receptor was also related to the transcription rate, and that the exon 2 region was related to receptor affinity and stability, and that the exon 3 region was related to mRNA processing/transport and mRNA stability. In this study, we newly demonstrated that there was no polymorphism in the exon 1 lesion of the brady-kinin B2 receptor in this population, so exon 1 polymorphism of the bradykinin B2 receptor had no effect on ACE-inhibitors-related cough, therefore, the transcriptional activity of the bradykinin B2 receptor promoter might be involved in the occurrence of ACE-inhibitor-related cough, and high transcriptional activity of the bradykinin B2 receptor promoter might induce ACE-inhibitor-related cough. We assume that the difference in the promoter activity associated with the difference in the promoter activity in bradykinin B2 receptor TT genotype and in bradykinin B2 receptor CC genotype affects the level of expression of bradykinin receptor protein and is involved in the development of cough. Recently a Chinese group 38 has reported that the bradykinin B2 receptor À58T/C polymorphism was not associated with ACE-inhibitor-related cough in Chinese female patients with non-insulindependent diabetes mellitus. However the background of their study population was quite different from that of our study population. This discrepancy may be the result of a selection bias in studying patients or population specificity.
Our present results indicate that among the polymorphisms analysed, the potentially and functionally significant polymorphism in the core promoter of the bradykinin B2 receptor À58T/C displays an increased prevalence of the À58T allele in the cough (+) patients as compared with the cough (À) patients, common genetic variants of the bradykinin B2 receptor explain the occurrence of ACE-inhibitor-related cough. Thus, the transcriptional activity of the bradykinin B2 receptor promoter seems to be involved in the appearance of ACEinhibitor-related cough. Our results also show that among the candidate gene for ACE-inhibitor-related cough, there were no differences in polymorphisms of ACE, angiotensin II receptors, or the bradykinin B2 receptor exon 1. It is important that a particular part of the newly discovered polymorphisms in a certain gene is unrelated to the occurrence of a disease, and the accumulation of such data is considered to lead to the elucidation of the really related part of pathology. In this study, we dare to show the negative data for the cause of ACEinhibitor-related cough, because the interrelation between polymorphisms and ACE-inhibitor-related cough is studied by only a limited number of researchers at this stage.
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Consequently, we conclude that the bradykinin B2 receptor À58T allele is involved in the occurrence of ACE-inhibitor-related cough, and that bradykinin B2 receptor promoter polymorphism appears to be a particularly important predictor of the risk of developing ACE-inhibitor-related cough. This new marker constitutes a valuable tool to detect patients at risk of developing ACE-inhibitor-related cough, and it might be useful for physicians to consider the bradykinin B2 receptor genotype when prescribing an ACE inhibitor to a hypertensive patient.
